Terazosin Dimer Impurity Dihydrochloride

• CAT Number: R063024
• CAS Number: 1486464-41-8
• Molecular Formula: C24H30Cl2N8O4
• Molecular Weight: 565.456
• Purity: ≥95%
• Synonyms: 2,2’-(1,4-Piperazinediyl)bis[6,7-dimethoxy-4-quinazolinamine] Dihydrochloride; USP Terazosin Related Compound C
• Target: Neuronal Signaling
• Storage: -20°C
• IUPAC Name: 2-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine;dihydrochloride
• InChI: InChI=1S/C24H28N8O4.2ClH/c1-33-17-9-13-15(11-19(17)35-3)27-23(29-21(13)25)31-5-7-32(8-6-31)24-28-16-12-20(36-4)18(34-2)10-14(16)22(26)30-24;;/h9-12H,5-8H2,1-4H3,(H2,25,27,29)(H2,26,28,30);2*1H
• InChIKey: SDPHRGYPGDUGEQ-UHFFFAOYSA-N
• SMILES: COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C4=NC5=CC(=C(C=C5C(=N4)N)OC)OC)N)OC.Cl.Cl

Terazosin dimer impurity dihydrochloride refers to a specific impurity containing terazosin, a medication used to treat hypertension and benign prostatic hyperplasia. This compound is a byproduct or intermediate formed during the synthesis of terazosin. Terazosin dimer impurity dihydrochloride is a subject of interest in pharmaceutical development and quality control, as impurities can affect drug purity and efficacy. Detailed characterization and quantification of impurities like this are crucial for ensuring drug safety and regulatory compliance. Research focuses on identifying, understanding, and minimizing impurities in pharmaceutical products.